Stuart J. Blakemore - Concepedia

Author

Stuart J. Blakemore

Also Known As

S Blakemore, S J Blakemore, S. Blakemore, S.J. Blakemore, Stuart Blakemore, Stuart J Blakemore, Stuart J. Blakemore, Stuart James Blakemore

Publications

830

Citations

H-Index

Concepts

All Affiliations

University of Southampton University of Cologne University Hospital Cologne University of Oxford Royal Bournemouth Hospital

About

Stuart J. Blakemore is an author at University of Southampton specializing in cell biology, medicine, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	175
2	Cell Biology	4	4	175
3	Immunology	2	2	111
4	Pathology	2	2	62
5	Cell Signaling	2	2	111

Stuart J. Blakemore

Publications

786

Citations

H-Index

Page 1

	Year	Citations
Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations Viktor Ljungström, Diego Cortese, Emma Young, Blood	2015	150
The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1 Marta Larráyoz, Stuart J. Blakemore, Rachel Dobson, Leukemia Hematological MalignancySf3b1 InhibitorMalignant Blood DisorderApoptosisImmunology	2015	101
Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1 Vivien Kohlhaas, Stuart J. Blakemore, Mona Al-Maarri, Blood	2020	86
Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia Helen Parker, Matthew Rose‐Zerilli, Marta Larráyoz, Leukemia	2016	79
Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features Pauline Robbe, Kate Ridout, Dimitrios V. Vavoulis, Nature Genetics	2022	70
EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia Emma Young, Daniel Noerenberg, Larry Mansouri, Leukemia Hematological MalignancyLymphoid NeoplasiaChronic Lymphocytic LeukemiaMedicineHematology	2016	52
Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial Stuart J. Blakemore, Ruth Clifford, Helen Parker, Leukemia	2020	49
Extracellular vesicles and PD-L1 suppress macrophages, inducing therapy resistance in <i>TP53</i>-deficient B-cell malignancies Elena Izquierdo, Daniela Vorholt, Stuart J. Blakemore, Blood	2022	34
Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: results from 3 UK clinical trials Tomasz K. Wojdacz, Harindra E. Amarasinghe, Latha Kadalayil, Blood Advances	2019	33
Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia Tatjana Pandzic, Jimmy Larsson, Liqun He, Clinical Cancer Research	2016	27

Page 1